Abstract
The mammalian target of rapamycin, mTOR, is a key node in cellular regulation: its dysregulation is important in a number of disease states, including various cancers. A recent study identifies a new partner and regulator of mTOR, which can alter the balance of signaling downstream of mTOR and appears to be important in certain cancers, such as multiple myelomas.
| Original language | English |
|---|---|
| Pages (from-to) | 61-63 |
| Number of pages | 3 |
| Journal | Journal of Molecular Cell Biology |
| Volume | 1 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 1 Dec 2009 |
| Externally published | Yes |
ASJC Scopus subject areas
- Molecular Biology
- Genetics
- Cell Biology